Drug intelligence / Profile preview

Synthetic Conjugated Estrogens, A

Development stage: Approved
Administration: Oral, Vaginal

Overview

Synthetic Conjugated Estrogens, A is a mixture of estrogen hormones used to treat moderate to severe hot flashes and other symptoms of menopause, including vaginal atrophy and dyspareunia. It is composed of a blend of synthetic estrogenic substances derived from plants, similar to Conjugated Equine Estrogens but not considered equivalent. The drug acts by mimicking the effects of natural estrogen in the body, thereby alleviating menopausal symptoms.

Brand names: Cenestin
Other names: Conjugated Estrogens Synthetic A

Targets

ESR1 (ERα)ESR2 (ERβ)

Beyond the preview

Go deeper on Synthetic Conjugated Estrogens, A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthetic Conjugated Estrogens, A.